|
|
|
11-50 employees
View all
|
|
Pharmaceuticals
|
|
United States
|
|
Palatin Technologies, Inc. (NYSE American: PTN) is a specialized biopharmaceutical company. PTN develops first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Our product and product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Learn more about Palatin Technologies here: https://www.palatin.com/Vyleesi®, our FDA-approved product, is the first and only on-demand treatment of acquired, generalized, hypoactive sexual desire disorder (HSDD), affecting 1 in 10 pre-menopausal women. Vyleesi® was approved by the Food and Drug Administration (FDA) in June 2019. We have licensed Chinese rights to Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. and Korean rights to Kwangdong Pharmaceutical Co., Ltd. We also have development programs or drug candidates for inflammatory disease indications, heart failure and fibrosis.To learn more about acquired, generalized, hypoactive sexual desire disorder (HSDD), visit here: https://www.unblush.com/To learn more about Vyleesi®, including Important Safety Information, visit here: https://www.vyleesi.com/
|
Palatin Technologies Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
100%
|
The widely used Palatin Technologies email format is {f}{last} (e.g. [email protected]) with 100% adoption across the company.
To contact Palatin Technologies customer service number in your country click here to find.
Carl Spana is the CEO of Palatin Technologies. To contact Carl Spana email at [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.